Clinical trials: Thoracic Diseases
Advanced Solid Tumors
A First-in-Humans Dose Finding Study for an Aryl Hydrocarbon Receptor Inhibitor (AhRi) in Patients With Advanced Cancer
In this study researchers want to gather relevant information regarding the safety of BAY2416964 and how well the drug works in participants with a type of solid tumors that cannot be cured by currently available drugs.
- Trial name
- NCT04069026
- Testing
- BAY2416964
- Where
- 17 sites in United States, Canada and 3 more
- Volunteers
- 78 people
- Sponsor
- Bayer
Non-Small-Cell Lung Carcinoma
A Study in Non-Small Cell Lung Cancer
The primary purpose of this study is to evaluate the hypothesis that cixutumumab given in combination with cisplatin and pemetrexed is superior to cisplatin and pemetrexed as first-line therapy for patients with advanced…
- Trial name
- NCT01232452
- Testing
- Pemetrexed, Cisplatin, Cixutumumab
- Where
- 44 sites in United States, Argentina and 10 more
- Volunteers
- 172 people
- Sponsor
- Eli Lilly and Company
Metastatic Non Small Cell Lung Cancer
C-TIL051 in Non-Small Cell Lung Cancer
The goal of this Phase 1 clinical study is test tumor infiltrating lymphocytes (known as C-TIL051) with NKTR-255 and anti-PD1 therapy for subjects with refractory non-small cell lung cancer. The purpose of this study is to: 1.
- Trial name
- NCT05676749
- Testing
- C-TIL051
- Where
- 3 sites in United States
- Volunteers
- 1 people
- Sponsor
- AbelZeta Inc.
Refractory Angina, Coronary Artery Disease
Investigational Trial to Evaluate XC001 Delivered Via an Cardiac Catheter in Subjects With Chronic Angina.
This is a two-part study, comprised of an initial open-label run-in phase (Part 1) in a subset of 3 subjects to provide first data regarding safety, and feasibility of the percutaneous endovascular catheter-facilitated…
- Trial name
- EXACT2 (NCT07048808)
- Testing
- XC001
- Where
- 14 sites in United States
- Volunteers
- 106 people
- Sponsor
- XyloCor Therapeutics, Inc.
Non-Small Cell Lung Cancer, Melanoma
A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma
To characterize safety and tolerability and identify a recommended dose and regimen for the LXH254 in combination with LTT462 or trametinib or ribociclib.
- Trial name
- NCT02974725
- Testing
- LXH254, LTT462, Trametinib
- Where
- 32 sites in United States, Australia and 9 more
- Volunteers
- 241 people
- Sponsor
- Novartis Pharmaceuticals
Non Small Cell Lung Cancer
Multicentre Study to Explore the Correlation Between Smoking Pattern and Clinical Efficacy of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) in Male Patients
The objective is to investigate the correlation between smoking pattern and clinical efficacy of EGFR TKIs in male patients with locally advanced or metastasized non-small cell lung cancer of adeno histology who have failed 1st…
- Trial name
- NCT00922025
- Where
- 6 sites in Taiwan
- Volunteers
- 186 people
- Sponsor
- AstraZeneca
Lung Cancer, Small Cell Lung Cancer
Phase II Study for Previously Untreated Subjects With Non Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC)
The purpose of the study is to determine whether ipilimumab given with paclitaxel/carboplatin has clinical benefit when compared with paclitaxel/carboplatin alone in patients with previously untreated lung cancer.
- Conditions
- Lung Cancer, Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung
- Trial name
- NCT00527735
- Testing
- Ipilimumab, Paclitaxel, Carboplatin
- Where
- 72 sites in United States, France and 6 more
- Volunteers
- 334 people
- Sponsor
- Bristol-Myers Squibb
High Risk Cancer, Lung Cancer
Retrospective Clinical Trial Comparing Radiologists' Diagnosis Accuracy in Lung Cancer Screening Population With and Without the Help of an AI/ML Tech-based SaMD
This is a two arm, randomized, controlled, blinded, multi-case multi reader (MRMC), retrospective study for the evaluation of the efficacy and safety of an AI/ML technology-based CADe/x developed to detect, localize and…
- Trial name
- RELIVE (NCT06751576)
- Testing
- Median LCS
- Where
- 5 sites in United States, Spain
- Volunteers
- 480 people, healthy volunteers welcome
- Sponsor
- Median Technologies
Non Small Cell Lung Cancer
Olmutinib 600 mg QD in Patients With T790M-positive NSCLC After Treatment With an EGFR-TKI
The purpose of this study is to evaluate the efficacy and safety of olmutinib 600 mg QD in patients with T790M-positive non-small cell lung cancer (NSCLC) after treatment with an epidermal growth factor receptor-tyrosine kinase…
- Trial name
- NCT04510415
- Testing
- Olmutinib
- Where
- 8 sites in South Korea
- Volunteers
- 2 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Solid Tumors, Non-small Cell Lung Cancer
Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors
This is an open-label, multi-center study of Phase Ib/II study to assess the efficacy and safety of Envafolimab combinded with Lenvatinib in the treatment of subjects with advanced solid tumors.
- Conditions
- Solid Tumors, Non-small Cell Lung Cancer, Renal Cell Carcinoma, Hepatocellular Carcinoma
- Trial name
- NCT05024214
- Testing
- Lenvatinib + Envafolimab, Sunitinib
- Where
- 23 sites in China
- Volunteers
- 170 people
- Sponsor
- 3D Medicines (Sichuan) Co., Ltd.
Solid Tumors, Non Small Cell Lung Carcinoma
Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid Tumors
Phase 1A/B, multicenter, open-label, non-randomized, dose-escalation oncology study to evaluate the administration of EC1456 in advanced solid tumors.
- Trial name
- NCT01999738
- Testing
- EC1456 and EC20
- Where
- 16 sites in United States
- Volunteers
- 93 people
- Sponsor
- Endocyte
Non-Small-Cell Lung Cancer
A Study of Pemetrexed Plus Carboplatin, or Pemetrexed Plus Cisplatin With Radiation Therapy Followed by Pemetrexed in Patients With Inoperable Non-Small-Cell Lung Cancer
The primary purpose of this study is to determine the 2-year survival rate of both of the chemotherapy regimens in patients with inoperable non-small-cell lung cancer.
- Trial name
- NCT00482014
- Testing
- pemetrexed, cisplatin, carboplatin
- Where
- 11 sites in United States, India
- Volunteers
- 120 people
- Sponsor
- Eli Lilly and Company
Melanoma, Non Small Cell Lung Cancer
Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory Cancer
The purpose of this study is to evaluate the safety of enoblituzumab (MGA271) in combination with Yervoy (ipilimumab) when given to patients with B7-H3-expressing melanoma, squamous cell carcinoma of the head and neck (SCCHN)…
- Trial name
- NCT02381314
- Testing
- enoblituzumab plus ipilimumab
- Where
- 10 sites in United States
- Volunteers
- 24 people
- Sponsor
- MacroGenics
ALK-positive Advanced NSCLC
Crizotinib Plus Pembrolizumab In Alk-Positive Advanced Non Small Cell Lung Cancer Patients
The purpose of this study has 2 phases, a Dose Finding Phase will determine the maximum tolerated dose . The Dose Expansion Phase will explore the safety, tolerability, and anti-tumor activity of the combination.
- Trial name
- NCT02511184
- Testing
- Crizotinib, Pembrolizumab
- Where
- 15 sites in United States
- Volunteers
- 9 people
- Sponsor
- Pfizer
Non-Small Cell Lung Cancer
FL-101 in Surgically Resectable Non-Small Cell Lung Cancer
Phase 2 trial to study FL-101 alone or in combination with nivolumab in patients who have surgically resectable Non-Small Cell Lung Cancer.
- Trial name
- NCT04758949
- Testing
- FL-101, Nivolumab
- Sponsor
- Flame Biosciences
Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung
Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers
This is an open-label, multi-center study to evaluate the safety, tolerability, and anti-tumor activity of SNK01 in combination with AFM24 in subjects with advanced or metastatic EGFR-expressing cancers.
- Conditions
- Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Advanced Solid Tumor
- Trial name
- NCT05099549
- Testing
- AFM24, SNK01
- Where
- 3 sites in United States
- Volunteers
- 11 people
- Sponsor
- NKGen Biotech, Inc.
Solid Tumor, Adult, Colorectal Cancer
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
The goal of this study is to test A2B395, an allogeneic logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorectal cancer (CRC), non-small cell lung cancer (NSCLC), head and neck squamous cell…
- Conditions
- Solid Tumor, Adult, Colorectal Cancer, Non-Small Cell Lung, NSCLC (Non-small Cell Lung Cancer)
- Trial name
- DENALI-1 (NCT06682793)
- Testing
- A2B395, xT CDx with HLA-LOH assay
- Where
- 10 sites in United States
- Volunteers
- 240 people
- Sponsor
- A2 Biotherapeutics Inc.
Non Small Cell Lung Cancer
Sunitinib Non Small Cell Lung Cancer Patients Over 70
The purpose of this research study is to find out what effects (good and bad) sunitinib has on patients and their NSCLC.
- Trial name
- NCT00864721
- Testing
- Sutent
- Where
- 13 sites in United States
- Volunteers
- 63 people
- Sponsor
- US Oncology Research
Non-Small Cell Lung Cancer
Pemetrexed and Best Supportive Care Versus Placebo and Best Supportive Care in Non-Small Cell Lung Cancer (NSCLC)
This study is a randomized Phase 3, double-blind study of maintenance pemetrexed plus best supportive care versus placebo plus best supportive care in NSCLC.
- Trial name
- NCT00102804
- Testing
- Pemetrexed, Best Supportive Care
- Where
- 73 sites in United States, Australia and 18 more
- Volunteers
- 663 people
- Sponsor
- Eli Lilly and Company
Lung Neoplasm Malignant
A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)
Researchers want to learn if MK-1084, the study medicine, can treat advanced or metastatic non-squamous NSCLC. MK-1084 is a targeted therapy, which is a treatment that works to control how specific types of cancer cells grow and…
- Trial name
- NCT07286149
- Testing
- MK-1084, Patritumab deruxtecan, Sacituzumab tirumotecan
- Where
- 29 sites in United States, Brazil and 9 more
- Volunteers
- 140 people
- Sponsor
- Merck Sharp & Dohme LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.